Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | HPGD | P15428 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.58 |
| ▸ | IKBKB | O14920 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | BRAF | P15056 | 1/20 | 0.54 |
| ▸ | MAOA | P21397 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29957616 | 1.00 | MAPT (0.63) | MAPTALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL2285909 | 0.89 | GAA (0.69) | MAPTALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1271606 | 0.87 | GAA (0.67) | MAPTALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL6289248 | 0.87 | GAA (0.67) | MAPTALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1270588 | 0.87 | GAA (0.67) | MAPTALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL6289955 | 0.87 | GAA (0.67) | MAPTALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL6293151 | 0.85 | GAA (0.64) | MAPTALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL6289853 | 0.85 | GAA (0.64) | MAPTALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL6290392 | 0.85 | GAA (0.64) | MAPTALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1269990 | 0.85 | GAA (0.64) | MAPTALDH1A1CYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5068437-A | Process for producing 2-(p-chlorophenoxy) aniline | AMERICAN CYANAMID COMPANY (US) | 1991-11-26 | — | — | US | claimed |
| EP-2950793-B1 | COMPOSITION FOR TREATMENT OF PATHOGENS THAT ARE RESISTANT TO TETRACYCLINES | BioVersys AG (CH) | 2020-04-01 | — | — | EP | disclosed |
| EP-3551628-A1 | INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | Celtaxsys Inc. (US) | 2019-10-16 | — | — | EP | disclosed |
| US-20190161471-A1 | INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | CELTAXSYS INC (US) | 2019-05-30 | — | — | US | disclosed |
| US-10202362-B2 | Inhibitors of leukotriene A4 hydrolase | CELTAXSYS, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| US-20180162836-A1 | INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | CELLTAXIS, LLC | 2018-06-14 | — | — | US | disclosed |
| WO-2018107153-A1 | INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | CELTAXSYS, INC. (US) | 2018-06-14 | — | — | WO | disclosed |
| US-9682079-B2 | Composition for treatment of pathogens that are resistant to tetracyclines | BioVersys AG (CH) | 2017-06-20 | — | — | US | disclosed |
| US-9682079-B2 | Composition for treatment of pathogens that are resistant to tetracyclines | BioVersys AG (CH) | 2017-06-20 | — | — | US | disclosed |
| US-9682079-B2 | Composition for treatment of pathogens that are resistant to tetracyclines | BioVersys AG (CH) | 2017-06-20 | — | — | US | disclosed |
| WO-2004002481-A1 | ARYL CARBONYL DERIVATIVES AS THERAPEUTIC AGENTS | NOVO NORDISK A/S (DK) | 2004-01-08 | — | — | WO | disclosed |
| EP-0633145-B1 | Thermal recording sheet | JUJO PAPER CO LTD (JP) | 1998-04-15 | — | — | EP | disclosed |
| US-5470816-A | Urea developers | NIPPON PAPER INDUSTRIES CO., LTD. (JP) | 1995-11-28 | — | — | US | disclosed |
| EP-0482508-B1 | Biscationic azo dyes and their intermediates | BASF AG (DE) | 1995-07-12 | — | — | EP | disclosed |
| US-5424404-A | Colorfastness, discoloration inhibition, red and yellow color; coloring paper, leather, printing on polymeric material | BASF AKTIENGESELLSCHAFT (DE) | 1995-06-13 | — | — | US | disclosed |
| EP-0633145-A1 | Thermal recording sheet | NIPPON PAPER INDUSTRIES CO., LTD. (JP) | 1995-01-11 | — | — | EP | disclosed |
| EP-0482508-A1 | Biscationic azo dyes and their intermediates | BASF Aktiengesellschaft (DE) | 1992-04-29 | — | — | EP | disclosed |
| US-5068437-A | Process for producing 2-(p-chlorophenoxy) aniline | AMERICAN CYANAMID COMPANY (US) | 1991-11-26 | — | — | US | disclosed |
| US-5068437-A | Process for producing 2-(p-chlorophenoxy) aniline | AMERICAN CYANAMID COMPANY (US) | 1991-11-26 | — | — | US | disclosed |
| US-4136033-A | DIAZO COUPLERS | SANDOZ LTD. (CH) | 1979-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190161471-A1 | INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | LTA4H, LTC4S, LTB4R | MAPT 4121/4885ALDH1A1 1041/4885CYP1A2 241/4885 |
| US-20180162836-A1 | INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | LTA4H, LTC4S, LTB4R | MAPT 4121/4885ALDH1A1 1041/4885CYP1A2 241/4885 |
| US-10202362-B2 | Inhibitors of leukotriene A4 hydrolase | LTA4H, LTC4S, LTB4R | MAPT 4121/4885ALDH1A1 1041/4885CYP1A2 241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.